While SGLT2 inhibitors have been included in international treatment guidelines for people with diabetes and CKD since 2018, only around 7% of these patients in the US are receiving these ...

Overall, the use of SGLT2 inhibitors was under 15% even for beneficiaries with diabetes, CKD, or heart failure. Of note, among beneficiaries with stage 3 CKD, prescribing of GLP-1 RAs increased ...

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to gather even more momentum after claiming FDA approval in chronic kidney disease (CKD).

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, cardiovascular disease and overall mortality are well known. Now ...

Medscape Medical News, April 11, 2024 SGLT2 Inhibitors Reduce Anemia Risk in Concomitant T2D, CKD Initiating treatment with SGLT2 inhibitors vs GLP-1 RAs was linked to a 19% reduced risk for ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease (CKD), according to Spherix Global Insights. The FDA expanded Ozempic ...

To TCTMD, Wiviott said there is a large body of evidence supporting the SGLT2 inhibitor drug class, noting the medications have been a “remarkable advance in diabetes management and the prevention and ...

despite receiving stable treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker and an SGLT2 inhibitor. The Explore-CKD trial is a randomized, double-blind ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, CVD and overall mortality.